The company reported fourth-quarter sales of $932.4 million, representing a 6.8% increase over the previous year and surpassing the $928.3 million consensus estimate. While net income dipped slightly to $225.2 million due to rising administrative and sales costs, adjusted earnings per share reached $4.53. This figure narrowly beat FactSet analyst projections of $4.51, signaling resilience despite macroeconomic pressures.

Sector Performance and Market Dynamics

Growth was largely propelled by the pharmaceutical and industrial segments, which both saw an 8% increase in sales. However, the company faced headwinds in the public sector, as sales to academic and government institutions declined by 2%. On a constant-currency basis, total quarterly sales grew by 6%, reflecting a steady appetite for Waters’ specialized healthcare and science products.

Looking ahead, Waters issued an optimistic outlook for 2026, forecasting constant-currency revenue growth between 5.5% and 7%. The company expects total annual revenue to land between $6.41 billion and $6.46 billion, with adjusted earnings projected in the range of $14.30 to $14.50 per share. This guidance suggests that the current momentum in commercial sectors will more than offset softer demand from research institutions.